|
 |
Volume 6, Number 1 (January 2009) | ||||||||
Letter from the Editor |
||||||||
5 |
Making our case The West Clinic, Memphis, TN With a fresh administration taking charge and a mandate from the American public for healthcare reform, 2009 is sure to be an interesting year. It’s too soon to read the tea leaves for a clear picture of what will transpire, but what is absolutely certain is that the landscape of medical practice will look different 12 months from now. The key is to get involved.
|
|||||||
Community Translations |
||||||||
11 |
Zoledronic acid improves disease-free survival in hormone-responsive early breast cancer Bisphosphonates are a highly effective treatment for reducing bone-related events in metastatic cancer, especially in breast cancer, multiple myeloma, and prostate cancer. With recent concerns being raised about osteonecrosis of the jaw, oncologists were becoming less enthusiastic about the use of zoledronic acid (Zometa). This is about to change with the three most-talked-about studies in breast cancer in the past year. | |||||||
FROM THE COMMUNITY ONCOLOGIST'S PERSPECTIVE Loma Linda University Cancer Center, Loma Linda, CA
| ||||||||
Review Article |
||||||||
24 |
Renal cell cancer: clinical presentation and prognosis—part I Greenebaum Cancer Center, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, and Baltimore VA Medical Center, Baltimore, MD Although advanced renal cell cancer (RCC) has been notoriously difficult to treat, with the identification of better therapeutic targets related to tumor angiogenesis and cellular metabolism, this paradigm is beginning to change, particularly for the most common subtype. In this first of a two-part article, an overview on the epidemiology, pathophysiology, clinical features, and prognostic factors is provided. Systemic therapies for RCC will be discussed in an upcoming issue.
| |||||||
Economics/Practice Management |
||||||||
33 |
Are your patients satisfied with your practice? How happy are your patients with the clinical and administrative services your practice provides? If you’re not asking that question, maybe you ought to be. Beginning with this article, Community Oncology takes you step by step through the process of surveying your patients and then responding to their concerns. In this first installment of our series on patient satisfaction—how to measure it and how to increase it—we focus on a Montana practice, which set out to perform a checkup on whether it is meeting patients’ needs.
| |||||||
Practical Biostatistics |
||||||||
36 |
Drug trial phases Department of Psychiatry, University of Toronto Senior Scientist, Kunin-Lunenfeld Applied Research Unit, Baycrest Centre, Toronto, Ontario, Canada, and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada Amusing, informative, practical. Not the way one would usually describe articles on biostatistics. But our authors make the study of this sometimes arcane topic a total pleasure. And, more importantly, the information will help you better evaluate studies and treat patients as community oncologists are increasingly asked to practice evidence-based medicine. In this first article, the authors cover drug testing phases: what they are and why they are needed.
| |||||||
Oncology Genetics |
||||||||
41 |
Hereditary diffuse gastric cancer: lifesaving potential of prophylactic gastrectomy Penn State Milton S. Hershey Medical Center, Hershey, PA The authors describe a family with a mutation in the E-cadherin gene, CDH1 which led to a diagnosis of early diffuse gastric cancer in two asymptomatic siblings. This family draws attention to a rare cancer predisposition syndrome and demonstrates the importance of presymptomatic genetic testing in making decisions regarding surveillance and the option of prophylactic surgery. Furthermore, this family highlights an increasingly common scenario in predisposition counseling, wherein it is appropriate to take a more directive shared decision-making approach in recommending a lifesaving intervention. | |||||||
COMMENTARY Clinical Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, and Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL
| ||||||||
Brief Communications |
||||||||
18 |
Optimizing the dasatinib dose regimen in chronic phase chronic myeloid leukemia: 100 mg once daily available for use Section of Stem Cell Transplant and Leukemia, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO In a recent randomized clinical trial, dasatinib showed superior response rates and PFS compared with high-dose imatinib. The newly recommended dose of 100 mg once daily in patients with chronic phase CML may offer an improved safety profile while maintaining efficacy compared with the previous 70-mg twice-daily dose
| |||||||
© 2009 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||||||
57 kb 
12.3 Mb (13 minutes, 26 seconds)